Product image of Moxifloxacina Krka (Moxifloxacin) supplied by GNH India

Moxifloxacina Krka

Active Ingredient:
Moxifloxacin
Origin:
EU

Moxifloxacina Krka (Moxifloxacin)

Moxifloxacin, the active ingredient in Moxifloxacina Krka, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a variety of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and skin‑structure infections, and complicated intra‑abdominal infections, in adult and appropriate pediatric patients.

GNH India supplies Moxifloxacina Krka as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across global markets while adhering to stringent quality standards and regulatory requirements.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Moxifloxacina Krka (moxifloxacin) is indicated for several bacterial infections affecting the respiratory, sinus, skin, and intra‑abdominal systems.
  • Community‑acquired pneumonia: effective eradication of the causative pathogens in adult patients.
  • Acute bacterial sinusitis: resolves infection and alleviates sinus inflammation.
  • Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and improves lung function.
  • Skin and skin‑structure infections: treats cellulitis, abscesses, and related conditions.
  • Complicated intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic organisms.

How It Works

  • Moxifloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA supercoiling and replication. Inhibition of these targets prevents DNA synthesis and transcription, leading to bacterial cell death. The dual inhibition enhances potency against both Gram‑positive and Gram‑negative organisms, including atypical respiratory pathogens. This mechanism results in a bactericidal effect that is concentration‑dependent and sustained after dosing.

Side Effects

Moxifloxacina Krka may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Nausea
  • Diarrhea
  • Headache
  • Dizziness
  • Abdominal pain
  • Rash

Serious or Rare Side Effects

  • Tendon rupture or inflammation
  • QT interval prolongation and cardiac arrhythmias
  • Severe allergic reactions such as anaphylaxis
  • Clostridioides difficile‑associated colitis
  • Hepatic dysfunction or jaundice
  • Stevens‑Johnson syndrome and toxic epidermal necrolysis

Precautions & Warnings

  • Before prescribing Moxifloxacina Krka, clinicians should consider several precautionary measures to ensure safe use.
  • Renal or hepatic impairment: adjust monitoring and consider dose modification.
  • History of tendon disorders: avoid use due to increased risk of tendon rupture.
  • QT prolongation risk: perform ECG monitoring in patients with cardiac risk factors.
  • Concomitant use of antacids containing aluminum or magnesium: separate administration by at least 2 hours.
  • Pregnancy and lactation: use only if potential benefits justify potential risks.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Moxifloxacina Krka can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Co‑administration with other fluoroquinolones: additive toxicity.
  • Use with drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias.
  • Combination with systemic corticosteroids: increased risk of tendon rupture.

Moderate Interactions (Monitor Closely)

  • Antacids containing aluminum or magnesium: reduce absorption; separate dosing by ≥2 hours.
  • Warfarin: may enhance anticoagulant effect; monitor INR closely.
  • Theophylline: may increase serum levels; observe for toxicity.

Frequently Asked Questions

Moxifloxacina Krka contains the fluoroquinolone moxifloxacin and is used to treat a range of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and skin‑structure infections, and complicated intra‑abdominal infections in adults and appropriate pediatric patients.

Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial DNA synthesis, leading to rapid bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative organisms.

The dose of Moxifloxacina Krka is determined by the prescribing clinician based on the specific infection, patient age, weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should set the dosing regimen.

Safety data for moxifloxacin in pregnancy and lactation are limited. The product should be used only if the potential benefits outweigh the possible risks to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Moxifloxacina Krka (moxifloxacin) offers a broader spectrum against atypical respiratory pathogens and enhanced activity against Gram‑positive organisms compared with older fluoroquinolones such as ciprofloxacin. It also has a lower propensity for inducing resistance in some strains, but shares class‑related safety considerations that require careful patient selection.

Store the product at room temperature, below 25 °C, in the original packaging. Protect it from moisture, excessive heat and direct sunlight. Keep the container tightly closed and out of reach of children.

Moxifloxacina Krka is taken orally as a tablet. Swallow the tablet whole with a full glass of water. It may be taken with or without food, but antacids containing aluminum or magnesium should be spaced at least two hours apart to avoid reduced absorption.

Serious adverse events include tendon rupture or inflammation, QT interval prolongation that can lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatic toxicity, and rare skin disorders like Stevens‑Johnson syndrome.

Moxifloxacina Krka is contraindicated in patients with known hypersensitivity to moxifloxacin or other fluoroquinolones, a history of tendon disorders, existing QT prolongation, or those receiving other QT‑prolonging drugs. Caution is also advised for children, pregnant or breastfeeding women unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT